{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:43:59Z","timestamp":1758815039000,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Clinically amyopathic dermatomyositis (CADM) patients often develop rapidly progressive interstitial lung disease (RP-ILD). A high level of anti-melanoma differentiation-associated gene 5 antibodies (anti-MDA5 Ab) before treatment is associated with RP-ILD development, a poor treatment response, and poor survival. The prognosis of CADM patients remains poor due to ILD even with combined intensive immunosuppressive therapy. Recently, several additional therapies, including tofacitinib (TOF) and plasma exchange (PE) therapy, have been reported to be effective. We herein report a case of CADM-ILD with a high level of anti-MDA5 Ab that was refractory to combined intensive immunosuppressive therapy including TOF, but successfully treated with PE. The following are possible reasons why TOF was ineffective: (1) cytokines that were not suppressed by TOF played an important role in RP-ILD; (2) TOF was administered later than previously reported; and (3) TOF did not suppress pathological substances such as antibodies. On the other hand, PE removes cytokines and various pathological substances. Therefore, PE may be a more reasonable additional therapy for intractable CADM-ILD.<\/jats:p>","DOI":"10.1093\/mrcr\/rxab054","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T06:48:24Z","timestamp":1641365304000},"page":"194-198","source":"Crossref","is-referenced-by-count":6,"title":["A case of clinically amyopathic dermatomyositis that was refractory to intensive immunosuppressive therapy including tofacitinib, but successfully treated with plasma exchange therapy"],"prefix":"10.1093","volume":"6","author":[{"given":"Daisuke","family":"Hiraoka","sequence":"first","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Shitsukawa, Toon, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-5011","authenticated-orcid":false,"given":"Jun","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Shitsukawa, Toon, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Horie","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Shitsukawa, Toon, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Shitsukawa, Toon, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Suemori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Shitsukawa, Toon, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Shitsukawa, Toon, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Shitsukawa, Toon, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"2022062410203738600_R1","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022062410203738600_R2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022062410203738600_R3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2022062410203738600_R4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"2022062410203738600_R5","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410203738600_R6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/s10165-011-0558-9","article-title":"Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140\/MDA5 autoantibodies","volume":"22","author":"Sato","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2022062410203738600_R7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima","year":"2016","journal-title":"Lupus"},{"key":"2022062410203738600_R8","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410203738600_R9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022062410203738600_R10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2022062410203738600_R11","article-title":"Efficiency of therapeutic plasma-exchange in acute interstitial lung disease, associated with polymyositis\/dermatomyositis resistant to glucocorticoids and immunosuppressive drugs: a retrospective study","volume":"6","author":"Ning","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2022062410203738600_R12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410203738600_R13","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410203738600_R14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2022062410203738600_R15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62:","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022062410203738600_R16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"2022062410203738600_R17","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/keq196","article-title":"Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410203738600_R18","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410203738600_R19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01685-5","article-title":"Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study","volume":"7","author":"Oda","year":"2017","journal-title":"Sci Rep"},{"key":"2022062410203738600_R20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/bjd.17079","article-title":"Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis","volume":"179","author":"Chen","year":"2018","journal-title":"Br J Dermatol"},{"key":"2022062410203738600_R21","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2022062410203738600_R22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol Rev"},{"key":"2022062410203738600_R23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol"},{"key":"2022062410203738600_R24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","article-title":"HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody","volume":"105","author":"Tanizawa","year":"2011","journal-title":"Respir Med"},{"key":"2022062410203738600_R25","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410203738600_R26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2018.05.010","article-title":"Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies","volume":"140","author":"Yamaguchi","year":"2018","journal-title":"Respir Med"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxab054\/42148832\/rxab054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/194\/44245126\/rxab054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/194\/44245126\/rxab054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T10:21:20Z","timestamp":1656066080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/6\/2\/194\/6497528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,4]]},"published-print":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxab054","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,1,4]]}}}